EMERYVILLE, Calif., April 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. , today announced that Paul E. Freiman, President and Chief Executive Officer, will deliver a corporate presentation at the Business Forum at the Biotechnology Industry Organization’s (BIO) Annual International Convention. The meeting will take place on April 9-12, 2006 in Chicago, Illinois.
The BIO Business Forum provides biotechnology companies the opportunity to meet with leaders in the investment, pharmaceutical, and biotechnology industries. Mr. Freiman’s presentation will take place on Wednesday, April 12, at 11:15 a.m. at McCormick Place South, Room B, Level 3, in Exhibit Hall A.
About Neurobiological Technologies, Inc.
NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President & CEO, of NeurobiologicalTechnologies, Inc., +1-510-595-6000; or Cheryl Schneider, VP - InvestorRelations, of Porter, Le Vay & Rose, Inc., +1-212-564-4700, forNeurobiological Technologies, Inc.
Web site: http://www.ntii.com//
